פרופ' מיטל גל-תנעמי

1.

Joint statement in support of hepatitis C human challenge studies.

Alter HJ, Barnes E, Biondi MJ, Cox AL, Eberts JD, Feld JJ, Liang TJ, Morrison J, Rice CM, Shoukry NH, Thomas DL, Van Gennip J, Weijer C; other signatories.

Lancet Gastroenterol Hepatol. 2023 Nov;8(11):967-969. doi: 10.1016/S2468-1253(23)00314-X. Epub 2023 Sep 21.

PMID: 37742699 No abstract available.

2.

Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis.

Domovitz T, Gal-Tanamy M.

J Clin Med. 2021 Feb 2;10(3):551. doi: 10.3390/jcm10030551.

PMID: 33540858 Free PMC article. Review.

3.

High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures.

Perez S, Lavi-Itzkovitz A, Gidoni M, Domovitz T, Dabour R, Khurana I, Davidovich A, Tobar A, Livoff A, Solomonov E, Maman Y, El-Osta A, Tsai Y, Yu ML, Stemmer SM, Haviv I, Yaari G, Gal-Tanamy M.

Cell Mol Gastroenterol Hepatol. 2023;16(1):63-81. doi: 10.1016/j.jcmgh.2023.03.004. Epub 2023 Mar 24.

PMID: 36965814 Free PMC article.

4.

Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running.

Gal-Tanamy M.

Gastroenterology. 2019 Aug;157(2):300-302. doi: 10.1053/j.gastro.2019.06.005. Epub 2019 Jun 13.

PMID: 31255661 No abstract available.

5.

Autoimmune Disease Classification Based on PubMed Text Mining.

Samuels H, Malov M, Saha Detroja T, Ben Zaken K, Bloch N, Gal-Tanamy M, Avni O, Polis B, Samson AO.

J Clin Med. 2022 Jul 26;11(15):4345. doi: 10.3390/jcm11154345.

PMID: 35893435 Free PMC article.

6.

Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity.

Safra M, Tamari Z, Polak P, Shiber S, Matan M, Karameh H, Helviz Y, Levy-Barda A, Yahalom V, Peretz A, Ben-Chetrit E, Brenner B, Tuller T, Gal-Tanamy M, Yaari G.

Front Immunol. 2023 Apr 19;14:1031914. doi: 10.3389/fimmu.2023.1031914. eCollection 2023.

PMID: 37153628 Free PMC article.

7.

Fold-change of chromatin condensation in yeast is a conserved property.

Yamin K, Bijlani S, Berman J, Soni A, Shlomai J, Buragohain BM, Werbner M, Gal-Tanamy M, Matityahu A, Onn I.

Sci Rep. 2022 Oct 17;12(1):17393. doi: 10.1038/s41598-022-22340-8.

PMID: 36253460 Free PMC article.

8.

Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.

Li R, Mor M, Ma B, Clark AE, Alter J, Werbner M, Lee JC, Leibel SL, Carlin AF, Dessau M, Gal-Tanamy M, Croker BA, Xiang Y, Freund NT.

Commun Biol. 2022 Aug 5;5(1):789. doi: 10.1038/s42003-022-03739-5.

PMID: 35931732 Free PMC article.

9.

Unmet needs in the post-DAA era: the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication.

Huang CF, Awad MH, Gal-Tanamy M, Yu ML.

Clin Mol Hepatol. 2024 Apr 26. doi: 10.3350/cmh.2024.0155. Online ahead of print.

PMID: 38665034 Review.

10.

Pseudoviruses for the assessment of coronavirus disinfection by ozone.

Zucker I, Lester Y, Alter J, Werbner M, Yecheskel Y, Gal-Tanamy M, Dessau M.

Environ Chem Lett. 2021;19(2):1779-1785. doi: 10.1007/s10311-020-01160-0. Epub 2021 Jan 13.

PMID: 33462542 Free PMC article.

11.

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.

Mor M, Werbner M, Alter J, Safra M, Chomsky E, Lee JC, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Ben-Shalom N, Navon M, Rafael D, Sharim H, Kiner E, Griffis ER, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dessau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT.

PLoS Pathog. 2021 Feb 11;17(2):e1009165. doi: 10.1371/journal.ppat.1009165. eCollection 2021 Feb.

PMID: 33571304 Free PMC article.

12.

BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women.

Rosenberg-Friedman M, Kigel A, Bahar Y, Werbner M, Alter J, Yogev Y, Dror Y, Lubetzky R, Dessau M, Gal-Tanamy M, Many A, Wine Y.

Nat Commun. 2021 Oct 28;12(1):6222. doi: 10.1038/s41467-021-26507-1.

PMID: 34711825 Free PMC article.

13.

Rapid electrochemical immunodetection of SARS-CoV-2 using a pseudo-typed vesicular stomatitis virus model.

Ashur I, Alter J, Werbner M, Ogungbile A, Dessau M, Gal-Tanamy M, Vernick S.

Talanta. 2022 Mar 1;239:123147. doi: 10.1016/j.talanta.2021.123147. Epub 2021 Dec 13.

PMID: 34920254 Free PMC article.

14.

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER).

Gastroenterology. 2022 Feb;162(2):454-467. doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

PMID: 34717923 Free PMC article.

15.

Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases.

Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Aharoni Golan M, Shachar E, Ben-Horin S, Maharshak N, Mor M, Ben Zvi H, Eliakim R, Barkan R, Sharar-Fischler T, Goren S, Krugliak N, Pichinuk E, Mor M, Werbner M, Alter J, Abu-Taha H, Kaboub K, Dessau M, Gal-Tanamy M, Cohen D, Freund NT, Dotan I, On Behalf Of The Responses To Covid-Vaccine Israeli Ibd.

Vaccines (Basel). 2022 Jul 26;10(8):1186. doi: 10.3390/vaccines10081186.

PMID: 35893835 Free PMC article.

16.

Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.

Perez S, Gal-Tanamy M.

Methods Mol Biol. 2019;1911:191-207. doi: 10.1007/978-1-4939-8976-8_13.

PMID: 30593627

17.

Dysregulation of the cohesin subunit RAD21 by Hepatitis C virus mediates host-virus interactions.

Perez S, Gevor M, Davidovich A, Kaspi A, Yamin K, Domovich T, Meirson T, Matityahu A, Brody Y, Stemmer SM, El-Osta A, Haviv I, Onn I, Gal-Tanamy M.

Nucleic Acids Res. 2019 Mar 18;47(5):2455-2471. doi: 10.1093/nar/gkz052.

PMID: 30698808 Free PMC article.

18.

HCV Infection Increases the Expression of ACE2 Receptor, Leading to Enhanced Entry of Both HCV and SARS-CoV-2 into Hepatocytes and a Coinfection State.

Domovitz T, Ayoub S, Werbner M, Alter J, Izhaki Tavor L, Yahalom-Ronen Y, Tikhonov E, Meirson T, Maman Y, Paran N, Israely T, Dessau M, Gal-Tanamy M.

Microbiol Spectr. 2022 Dec 21;10(6):e0115022. doi: 10.1128/spectrum.01150-22. Epub 2022 Oct 31.

PMID: 36314945 Free PMC article.

19.

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M.

PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. eCollection 2019 Jun.

PMID: 31216276 Free PMC article.

20.

Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.

Ninio L, Nissani A, Meirson T, Domovitz T, Genna A, Twafra S, Srikanth KD, Dabour R, Avraham E, Davidovich A, Gil-Henn H, Gal-Tanamy M.

Cells. 2019 Nov 5;8(11):1395. doi: 10.3390/cells8111395.

PMID: 31694343 Free PMC article.

21.

Antibody Repertoire Analysis of Hepatitis C Virus Infections Identifies Immune Signatures Associated With Spontaneous Clearance.

Eliyahu S, Sharabi O, Elmedvi S, Timor R, Davidovich A, Vigneault F, Clouser C, Hope R, Nimer A, Braun M, Weiss YY, Polak P, Yaari G, Gal-Tanamy M.

Front Immunol. 2018 Dec 21;9:3004. doi: 10.3389/fimmu.2018.03004. eCollection 2018.

PMID: 30622532 Free PMC article.

22.

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors.

Mor M, Werbner M, Alter J, Safra M, Chomsky E, Hada-Neeman S, Polonsky K, Nowell CJ, Clark AE, Roitburd-Berman A, Shalom NB, Navon M, Rafael D, Sharim H, Kiner E, Griffis E, Gershoni JM, Kobiler O, Leibel SL, Zimhony O, Carlin AF, Yaari G, Dassau M, Gal-Tanamy M, Hagin D, Croker BA, Freund NT.

bioRxiv [Preprint]. 2020 Oct 6:2020.10.06.323634. doi: 10.1101/2020.10.06.323634.

Update in: PLoS Pathog. 2021 Feb 11;17(2):e1009165. doi: 10.1371/journal.ppat.1009165.

PMID: 33052341 Free PMC article. Preprint.

23.

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era.

Huang CF, Awad MH, Gal-Tanamy M, Yu ML.

Clin Mol Hepatol. 2024 Jul 1. doi: 10.3350/cmh.2024.0472. Online ahead of print.

PMID: 38946463 No abstract available.

24.

Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxin.

Shapira A, Shapira S, Gal-Tanamy M, Zemel R, Tur-Kaspa R, Benhar I.

PLoS One. 2012;7(2):e32320. doi: 10.1371/journal.pone.0032320. Epub 2012 Feb 16.

PMID: 22359682 Free PMC article.

25.

Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.

Gal-Tanamy M, Zemel R, Bachmatov L, Jangra RK, Shapira A, Villanueva RA, Yi M, Lemon SM, Benhar I, Tur-Kaspa R.

Antiviral Res. 2010 Oct;88(1):95-106. doi: 10.1016/j.antiviral.2010.08.001. Epub 2010 Aug 10.

PMID: 20705106 Free PMC article.

26.

Single chain antibodies specific for fatty acids derived from a semi-synthetic phage display library.

Gargir A, Ofek I, Meron-Sudai S, Tanamy MG, Kabouridis PS, Nissim A.

Biochim Biophys Acta. 2002 Jan 15;1569(1-3):167-73. doi: 10.1016/s0304-4165(01)00245-8.

PMID: 11853971

27.

In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19450-5. doi: 10.1073/pnas.0809879105. Epub 2008 Dec 3.

PMID: 19052239 Free PMC article.

28.

Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies.

Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, Li SH, Patel AH, Ball JK, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6061-6. doi: 10.1128/JVI.02475-07. Epub 2008 Apr 9.

PMID: 18400849 Free PMC article.

29.

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.

Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R.

Hepatology. 2011 Nov;54(5):1570-9. doi: 10.1002/hep.24575.

PMID: 21793032

30.

HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.

Gal-Tanamy M, Zemel R, Berdichevsky Y, Bachmatov L, Tur-Kaspa R, Benhar I.

J Mol Biol. 2005 Apr 15;347(5):991-1003. doi: 10.1016/j.jmb.2005.02.020.

PMID: 15784258

31.

A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Foung SK.

J Virol. 2008 Jun;82(12):6067-72. doi: 10.1128/JVI.00252-08. Epub 2008 Apr 2.

PMID: 18385242 Free PMC article.

32.

Inhibition of hepatitis C virus RNA replicons by peptide aptamers.

Trahtenherts A, Gal-Tanamy M, Zemel R, Bachmatov L, Loewenstein S, Tur-Kaspa R, Benhar I.

Antiviral Res. 2008 Mar;77(3):195-205. doi: 10.1016/j.antiviral.2007.12.013. Epub 2008 Jan 22.

PMID: 18243349

33.

Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.

Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D, Zemel R, Tur-Kaspa R, Benhar I.

PLoS One. 2011 Jan 14;6(1):e15916. doi: 10.1371/journal.pone.0015916.

PMID: 21264238 Free PMC article.